#Open journalism No news is bad news

Your contributions will help us continue to deliver the stories that are important to you

Support The Journal
Dublin: 18°C Tuesday 22 June 2021
Advertisement

Pfizer vaccine can be kept in fridges for up to a month rather than just five days, EU medicines regulator says

The European Medicines Agency said this could improve the flexibility in countries’ vaccine rollout.

THE EU’S DRUG agency has approved the storage of the Pfizer-BioNTech coronavirus vaccine in fridges for up to a month, in a move that should boost its rollout across the bloc, including in Ireland.

The storage period in fridges of unopened vials of the vaccine, which initially had to be stored in super-cooled freezers, had been lengthened from five days, the European Medicines Agency said.

“Increased flexibility in the storage and handling of the vaccine is expected to have a significant impact on planning and logistics of vaccine rollout in EU member states,” the Amsterdam-based EMA said.

“This change extends the approved storage period of the unopened thawed vial at two-eight degrees Celsius [i.e. in a normal fridge after taking out of deep-freeze conditions] from five days to one month (31 days),” it added.

The Pfizer vaccine’s high effectiveness against coronavirus has been tempered by the difficulty of storing and transporting the jab due to the need for the super-cold conditions originally required.

In March the EMA said however that the jab could be stored in normal freezers, before allowing it to remain for fridges for short periods of time.

German developer BioNTech, which makes the vaccine along with US pharma giant Pfizer, said the EMA had made the decision based on new information it had supplied.

“The change of the storage conditions is based on new data from stability studies that confirmed the product quality for 31 days,” it said in a statement.

#Open journalism No news is bad news Support The Journal

Your contributions will help us continue to deliver the stories that are important to you

Support us now

Separately, a new study from the US today found that both the Pfizer and Moderna vaccines should remain highly effective against two coronavirus variants first identified in India.

The lab-based study was carried out by the NYU Grossman School of Medicine and NYU Langone Center and is considered preliminary because it has not yet been published in a peer-reviewed journal.

“What we found is that the vaccine’s antibodies are a little bit weaker against the variants, but not enough that we think it would have much of an effect on the protective ability of the vaccines,” senior author Nathaniel “Ned” Landau told AFP today.

 © – AFP, 2021

About the author:

AFP

Read next:

COMMENTS (11)

This is YOUR comments community. Stay civil, stay constructive, stay on topic. Please familiarise yourself with our comments policy here before taking part.
write a comment

    Leave a commentcancel